I've been analyzing data from Remdesivir trial over and

New Post Public Reply Private Reply Replies (0) Message Board
aragon1959
536
I've been analyzing data from Remdesivir trial over and over again since this morning hype news.
This is negative trial IMO
Survival ( mortality) difference ( 8% vs 11.6%) is not statistically significant .
Duration of symptoms (11 vs 15 days) not statistically significance .
QoL data , including toxicity not revealed and we all know how Remdesivir can be toxic
I think this is failed study and sooner rather than later we will know the truth .
I think this news was released ( the preliminary results ) to give a false ( unfortunately) hopes, to quiet the market and for other less precise reasons.
It also tells us IPIX investors , how frantic and desperate gov's are to find the treatment.
Science is on our side and B will win big time!!!!!!
Stay all healthy and safe
aragon

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials